These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31506634)

  • 21. Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease.
    Marti-Aguado D; Rodríguez-Ortega A; Mestre-Alagarda C; Bauza M; Valero-Pérez E; Alfaro-Cervello C; Benlloch S; Pérez-Rojas J; Ferrández A; Alemany-Monraval P; Escudero-García D; Monton C; Aguilera V; Alberich-Bayarri Á; Serra MÁ; Marti-Bonmati L
    Aliment Pharmacol Ther; 2021 Jan; 53(1):160-171. PubMed ID: 32981113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
    Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated whole slide image analysis for a translational quantification of liver fibrosis.
    Serdjebi C; Bertotti K; Huang P; Wei G; Skelton-Badlani D; Leclercq IA; Barbes D; Lepoivre B; Popov YV; Julé Y
    Sci Rep; 2022 Nov; 12(1):17935. PubMed ID: 36333365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
    Waghorn PA; Ferreira DS; Erstad DJ; Rotile NJ; Masia R; Jones CM; Tu C; Sojoodi M; Chen YI; Schlerman F; Wellen J; Martinez RVP; Tanabe KK; Fuchs BC; Caravan P
    Sci Rep; 2021 Mar; 11(1):6105. PubMed ID: 33731798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep learning enables pathologist-like scoring of NASH models.
    Heinemann F; Birk G; Stierstorfer B
    Sci Rep; 2019 Dec; 9(1):18454. PubMed ID: 31804575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
    Kennedy L; Meadows V; Sybenga A; Demieville J; Chen L; Hargrove L; Ekser B; Dar W; Ceci L; Kundu D; Kyritsi K; Pham L; Zhou T; Glaser S; Meng F; Alpini G; Francis H
    Hepatology; 2021 Jul; 74(1):164-182. PubMed ID: 33434322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study.
    Eriksen PL; Thomsen KL; Larsen LP; Grønbaek H; Vilstrup H; Sørensen M
    Aliment Pharmacol Ther; 2019 Jul; 50(1):84-92. PubMed ID: 31099410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Kleiner DE; Brunt EM; Van Natta M; Behling C; Contos MJ; Cummings OW; Ferrell LD; Liu YC; Torbenson MS; Unalp-Arida A; Yeh M; McCullough AJ; Sanyal AJ;
    Hepatology; 2005 Jun; 41(6):1313-21. PubMed ID: 15915461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
    World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
    Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
    Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
    Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.